---
authors:
- Ebell, Mark H
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/36260879/
file_path: 2022/10/aducanumab-is-not-effective-for-mild-cognitive-impairment-or.md
issue: '4'
keywords:
- Cognitive Dysfunction
- Antibodies, Monoclonal, Humanized
- Humans
- Alzheimer Disease
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Alzheimer Disease
- Cognitive Dysfunction
- Antibodies, Monoclonal, Humanized
original_format: PubMed
pages: 462-463
patient_population: Adults
peer_reviewed: true
pmid: '36260879'
processed_date: '2025-07-30'
publication_date: '2022-10-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Aducanumab Is Not Effective for Mild Cognitive Impairment or Mild Alzheimer
  Dementia and Has Major Safety Issues.
topics:
- Family Medicine
volume: '106'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '36260879'
  title: Aducanumab Is Not Effective for Mild Cognitive Impairment or Mild Alzheimer
    Dementia and Has Major Safety Issues.
  authors:
  - last_name: Ebell
    fore_name: Mark H
    initials: MH
    affiliation: University of Georgia, Athens, Ga.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '106'
    issue: '4'
  publication_info:
    year: '2022'
    month: '10'
    full_date: '2022-10-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Alzheimer Disease
    major_topic: true
    qualifiers:
    - qualifier: drug therapy
      major_topic: false
    - qualifier: psychology
      major_topic: false
  - descriptor: Cognitive Dysfunction
    major_topic: true
    qualifiers:
    - qualifier: drug therapy
      major_topic: false
  - descriptor: Antibodies, Monoclonal, Humanized
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  publication_types: *id001
related_articles:
- pmid: '36260879'
  title: Aducanumab Is Not Effective for Mild Cognitive Impairment or Mild Alzheimer
    Dementia and Has Major Safety Issues.
  authors:
  - name: Ebell MH
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2022 Oct
- pmid: '34324167'
  title: 'Aducanumab: First Approval.'
  authors:
  - name: Dhillon S
    authtype: Author
    clusterid: ''
  source: Drugs
  pubdate: 2021 Aug
- pmid: '35491796'
  title: Making the Case for the Accelerated Withdrawal of Aducanumab.
  authors:
  - name: Whitehouse PJ
    authtype: Author
    clusterid: ''
  - name: Saini V
    authtype: Author
    clusterid: ''
  source: J Alzheimers Dis
  pubdate: '2022'
- pmid: '34499725'
  title: Representativeness of Participants Eligible to Be Enrolled in Clinical Trials
    of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With
    Alzheimer Disease and Mild Cognitive Impairment.
  authors:
  - name: Anderson TS
    authtype: Author
    clusterid: ''
  - name: Ayanian JZ
    authtype: Author
    clusterid: ''
  - name: Souza J
    authtype: Author
    clusterid: ''
  - name: Landon BE
    authtype: Author
    clusterid: ''
  source: JAMA
  pubdate: 2021 Oct 26
- pmid: '34750815'
  title: '"Real-world" eligibility for aducanumab depends on clinical setting and
    patients'' journey.'
  authors:
  - name: Padovani A
    authtype: Author
    clusterid: ''
  - name: Caratozzolo S
    authtype: Author
    clusterid: ''
  - name: Rozzini L
    authtype: Author
    clusterid: ''
  - name: Pilotto A
    authtype: Author
    clusterid: ''
  - name: Benussi A
    authtype: Author
    clusterid: ''
  - name: Tedeschi G
    authtype: Author
    clusterid: ''
  source: J Am Geriatr Soc
  pubdate: 2022 Feb
---

# Aducanumab Is Not Effective for Mild Cognitive Impairment or Mild Alzheimer Dementia and Has Major Safety Issues.

**Authors:** Ebell, Mark H

**Published in:** American family physician | Vol. 106, No. 4 | 2022-10-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/36260879/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Alzheimer Disease, Cognitive Dysfunction, Antibodies, Monoclonal, Humanized

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36260879/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
